Melanoma & Skin Cancer

Jeffrey S. Weber, MD, PhD, discusses the results of the phase 3 COMBI-AD trial with dabrafenib plus trametinib in patients with resected, stage III BRAF V600E/K–mutant melanoma.

sFRP2-mediated angiogenesis offset decreased VEGF-mediated angiogenesis in older patients with cutaneous melanoma compared with younger patients, leading to poorer disease-free survival and overall survival with adjuvant bevacizumab.

After 15 years as a surgeon, Jeffrey M. Farma, MD, says he's still learning how to treat patients with cancer. As fellowship director of the Complex General Surgical Oncology Fellowship at Fox Chase Cancer Center, he expects his trainees to be prepared to do the same.

An ongoing, collaborative clinical trial has been expanded to evaluate the investigational protein kinase C inhibitor IDE196 in combination with the multikinase inhibitor crizotinib (Xalkori) for patients with GNAQ- or GNA11-mutated solid tumors, including metastatic uveal melanoma , skin melanoma, lung cancer, and colorectal cancer.

Suthee Rapisuwon, MD, reviews management strategies under exploration for mucosal, acral, and uveal melanoma.

Geoffrey T. Gibney, MD, provides an update on the evolution of frontline treatment in metastatic melanoma.

Alexander N. Shoushtari, discusses the rationale for the ​phase 3 CheckMate-067 trial in advanced melanoma.

The immunotherapy combination of adjuvant nivolumab and ipilimumab failed to lead to a statistically significant improvement in recurrence-free survival in the intent-to-treat population of patients with resected stage IIIB/C/D or stage IV melanoma.

Michael B. Atkins, MD, discusses the clinical impact of key adjuvant and neoadjuvant data in the melanoma space, as well as the risks and benefits of both approaches.

Isabella C. Glitza Oliva, MD, PhD, MS, discusses ​the potential utility of pembrolizumab in combination with selinexor in advanced melanoma.

Alexander M. M. Eggermont, MD, PhD, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, ​evaluating adjuvant pembrolizumab versus placebo, in advanced melanoma.

Mattia Garutti, MD, discusses the potential shift to neoadjuvant therapy in melanoma.

Alexander N. Shoushtari, MD, discusses the design of the ​phase 3 CheckMate-067 trial in advanced melanoma. 

Spartalizumab plus dabrafenib did not significantly improve progression-free survival over dabrafenib/trametinib in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma.

Early findings from a phase II efficacy and safety study may be the first step in developing a definitive rationale for sequencing targeted therapies and immunotherapies in patients with metastatic melanoma.

The PD-1 antibody cemiplimab established encouraging clinical activity in patients with locally advanced basal cell carcinoma who progress on or are intolerant to hedgehog inhibitors, regardless of PD-L1 expression.

Alexander J. Stratigos, MD, discusses the rationale to evaluate cemiplimab-rwlc in locally advanced basal cell carcinoma.